#Canada #Ontario #Neuromod #Lenire #Tinnitus

Lenire Tinnitus Treatment Device Now Available in Canada

In a significant advancement for tinnitus management, Neuromod Devices has introduced the Lenire tinnitus treatment device to Canada, making it now available through 21 specialized clinics in key provinces such as Ontario, British Columbia, Alberta, Manitoba, and Québec. Tinnitus, commonly described as a persistent ringing, hissing, or buzzing in the ears, affects nearly half of Canadian adults at some point in their lives, with the Canadian Health Measures Survey indicating that 43% of Canadians have experienced this condition. The urgency for effective treatment is underscored by the fact that approximately 37% of Canadians reported experiencing tinnitus in the past year alone.

Clinical data regarding Lenire shows promising results. In two major clinical trials involving 517 participants, 84% reported sustained relief from tinnitus symptoms lasting over a year. Additionally, an independent peer-reviewed study indicated that an impressive 91.5% of patients experienced significant improvement in their tinnitus following treatment with Lenire. A Toronto-based tinnitus patient, Jim Gray, expressed his gratitude, stating, “Lenire has been a miracle that has changed my life.”

The Lenire device employs an innovative approach known as bimodal neuromodulation. It combines mild stimulation to the tongue through a unique device component called the Tonguetip® with auditory stimuli, effectively training the brain and reducing the perception of tinnitus. This method marks a departure from traditional sound-therapy techniques and positions Lenire as a cutting-edge, non-invasive alternative.

The demand for effective tinnitus treatment in Canada is growing. Dr. Ross O'Neill, the founder and CEO of Neuromod, acknowledged the increasing inquiries from Canadians requesting the availability of Lenire. “Today, I am proud to say we have delivered for these people, the millions of others living with tinnitus, and for their healthcare providers. A high prevalence of tinnitus in Canada is driving demand for clinically proven treatment options,” he stated.

Lenire’s launch in Canada followed meticulous preparations, including compliance audits and regulatory approvals that affirm its adherence to international safety and quality standards. The device gained notable recognition after securing De Novo approval from the U.S. Food and Drug Administration (FDA) in 2023, making it the first bimodal neuromodulation device to earn this distinction. This approval was based on the outcomes of a controlled clinical trial that demonstrated Lenire's superiority in tinnitus treatment compared to conventional sound therapy methods.

In addition to its launch in Canada, Lenire has gained traction internationally, having already been introduced in other countries such as The Netherlands and Portugal, with ongoing expansions planned in the United States as well. Neuromod is determined to partner with leading tinnitus care clinics across Canada to ensure that this revolutionary device is accessible to those in need.

Patient outcomes stemming from Lenire's use align closely with clinical trial results. For instance, a peer-reviewed study published in Nature Communications Medicine reported that among 220 patients with bothersome tinnitus treated at Alaska Hearing Tinnitus, 91.5% experienced clinically meaningful reductions in their symptoms. Furthermore, a separate publication in the American Journal of Audiology detailed that 81.8% of 140 problematic tinnitus patients receiving treatment at New York Hearing Doctors reported substantial relief.

The increasing recognition of tinnitus and the necessary treatments is evident as healthcare providers note a rise in patients seeking help for their ringing ears. Ron Abish, founder and CEO of Hearing Solutions, observed, “We are seeing more patients presenting to our clinicians with tinnitus as their primary concern, reflecting increased awareness and demand for care.”

Lenire’s availability comes as a welcome relief for many Canadians suffering from chronic tinnitus, with trained hearing care professionals across the country prepared to offer assessments and treatment plans. Patients interested in experiencing the benefits of Lenire can find a local clinic by visiting Lenire’s website.

As awareness grows and demand for effective treatments escalate, the Lenire device illustrates the potential for technological advancements to significantly improve the quality of life for those impacted by this condition. Neuromod Devices continues to lead the way in developing pioneering solutions aimed at addressing the challenges faced by tinnitus patients, fostering hope for lasting relief.